Here, by state-of-the-art mass spectrometry-based quantitative proteomic technology, we systematically screened the potential neo-substrates of a novel thalidomide derived cereblon modulator CC-885.
We isolated PDGFRβ+ mural cells from tumor-adjacent normal human brain, lung, and kidney tissues. After lysis, we used LC-MS to profile differentially expressed proteins across these three cell types.
